Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 338

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 338
---
                 2,820  
  VAT refund                                                              1,614                 1,037       880              
  Trade account receivables (3)                                           3,080                15,233       650              
  Prepayments made to suppliers (4)                                       2,652                 3,374       509              
  Receivables and others - current                                       38,345                55,557                 4,972  
  Prepayments made to suppliers (4)                               —                     —                             1,362  
  Research tax credit (1)                                                13,018                 9,800                 7,464  
  Prepaid expenses (2)                                                    1,081       754                   502              
  Receivables and others - non-current                                   14,099                10,554                 9,328  
  Trade receivables and others                                           52,445                66,111                14,300  

(1) In accordance with the principles described in Note 2. q, the research tax credit (Crédit d’ Impôt Recherche or “ CIR”) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of CIR recognized as current receivables as of December 31, 2023 comprises the research tax credit for the 2019 and 2020 tax years, for which the three years period has expired as of December 31, 2023. The CIR for 2019 was reimbursed in February 2024 for an amount of € 16,737 12,755 10,302 9,167 95 5 3-year 490. The amount of € 7,464

(2) As of December 31 2024, December 31, 2023, and December 31, 2022 the prepaid expenses includes amounts of € 754 1,005 1,256 two two five-year

(3) As of December 31, 2024, the amount breaks mainly down as receivables from AstraZeeca for an amount of 644 15,000 1,775 1,303

(4) At 31 December 2024, advances had been paid to suppliers. These advances will be deducted from subsequent payments in accordance with the terms of the contracts.

Trade receivables and others have payment terms of less than one year. No